DAVIE, A.; TRAORÉ, S.; GIOVANNITTI, M.; POMPILIO, G.; LAMBTON, M.; CAKAR, E.; CHATTERJEE, A. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy. Global and Regional Health Technology Assessment, [S. l.], v. 10, n. 1, p. 62–69, 2023. DOI: 10.33393/grhta.2023.2561. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/2561. Acesso em: 3 jul. 2024.